ImmunityBio, Inc. IBRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s cash & equivalents?
- ImmunityBio, Inc. (IBRX) reported cash & equivalents of $205.19M in Q1 2026.
- How has ImmunityBio, Inc.'s cash & equivalents changed year-over-year?
- ImmunityBio, Inc.'s cash & equivalents increased by 238.3% year-over-year, from $60.66M to $205.19M.
- What is the long-term trend for ImmunityBio, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s cash & equivalents has grown at a 20.4% compound annual growth rate (CAGR), from $34.92M to $88.33M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and ability to fund operations, while a decrease may signal a need for capital raises or reduced R&D spending.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances relative to burn rates to ensure multi-year operational runway.